Health-related Quality of Life of Patients With Locally Advanced Thyroid Cancer Receiving Targeted Therapy
Overview
- Phase
- N/A
- Intervention
- Tyrosine kinase inhibitor drugs.
- Conditions
- Thyroid Cancer
- Sponsor
- Fujian Cancer Hospital
- Enrollment
- 80
- Locations
- 1
- Primary Endpoint
- the global status of QLQ C30 questionnaire
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
The purpose of this study was to explore the changes of health-related quality of life (HRQOL) in patients with locally advanced thyroid cancer (LATC) receiving TKI drugs (anlotinib, lenvatinib, etc.).
Detailed Description
Surgical resection is the cornerstone of treatment for thyroid cancer. However, some patients present with locally advanced disease at the time of diagnosis, and they are not eligible for radical resection. Another patients still had the risk of recurrence after surgery, endocrine therapy and iodine-131 treatment. Tyrosine kinase inhibitors (TKI) have been proved to be effective in thyroid cancer patients. However, it was still unclear whether TKI drugs had influence on the HRQOL of LATC patients. The purpose of this study was to explore the changes of health-related quality of life (HRQOL) in patients with locally advanced thyroid cancer (LATC) receiving TKI drugs (anlotinib, lenvatinib, etc.).Participants enroll the study after informed consent, and quality of life will be assessed using quality of life questionnaires EORTC QLQ C30, and EORTC THY 47 before surgery, and 1,3,6 and 12 months after treatment.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients age (18-70 year old)
- •Diagnosis of locally advanced thyroid cancer
- •Patient receiving TKI drugs.
Exclusion Criteria
- •pregnancy or breastfeeding women;
- •history of other malignant diseases, unstable angina, myocardial infarction, cerebral infarction or cerebral hemorrhage within 6 months; (3) patients missing questionnaires greater than 3 times.
Arms & Interventions
TKI group
patients with LATC receiving Tyrosine kinase inhibitor drugs.
Intervention: Tyrosine kinase inhibitor drugs.
Outcomes
Primary Outcomes
the global status of QLQ C30 questionnaire
Time Frame: 1 year
Change in global HRQOL score between baseline and at 12 months after treatment. A change of more than 10% is set as a limit for a significant change
Secondary Outcomes
- Change in fatigue score(1 year)
- Adversed events of TKI.(1 year)